Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study. - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2023

Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.

Fichier non déposé

Dates et versions

hal-04326230 , version 1 (06-12-2023)

Identifiants

Citer

Lucia Carril-Ajuria, Marie Naigeon, Cecile Dalban, Aude Desnoyer, Nathalie Rioux-Leclercq, et al.. Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients (pts) with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study.. Genitourinary Cancers Symposium, Feb 2023, San Francisco, United States. ⟨10.1200/JCO.2023.41.6_suppl.724⟩. ⟨hal-04326230⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More